Health Care & Life Sciences » Pharmaceuticals | Guizhou Yibai Pharmaceutical Co. Ltd.

Guizhou Yibai Pharmaceutical Co. Ltd. A | Income Statement

Fiscal year is January-December. All values CNY Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
2,741
3,157
3,247
3,625
3,739
3,826
Cost of Goods Sold (COGS) incl. D&A
521
600
667
911
1,011
1,156
Gross Income
2,221
2,557
2,581
2,714
2,728
2,669
SG&A Expense
1,682
1,953
2,298
2,152
2,219
2,359
EBIT
523
536
250
560
506
278
Unusual Expense
-
-
8
14
6
1,026
Non Operating Income/Expense
-
21
7
7
58
22
Interest Expense
23
49
57
63
83
76
Pretax Income
506
546
227
486
487
786
Income Tax
84
75
35
90
79
101
Equity in Affiliates
10
10
1
3
1
-
Consolidated Net Income
431
481
192
393
408
684
Net Income
429
478
189
385
388
725
Net Income After Extraordinaries
429
478
189
385
388
725
Net Income Available to Common
429
478
189
385
388
725
EPS (Basic)
0.60
0.61
0.24
0.49
0.49
0.92
Basic Shares Outstanding
721
786
792
792
792
792
EPS (Diluted)
0.60
0.61
0.24
0.49
0.49
0.92
Diluted Shares Outstanding
721
786
792
792
792
792
EBITDA
578
627
351
681
670
481
Other Operating Expense
16
68
33
2
3
32
Non-Operating Interest Income
2
9
5
4
13
10
Minority Interest Expense
2
3
3
9
20
41

About Guizhou Yibai Pharmaceutical Co.

View Profile
Address
No. 220-1 Baiyun Avenue
Guiyang Guizhou 550008
China
Employees -
Website http://e.gzcci.com
Updated 07/08/2019
Guizhou Yibai Pharmaceutical Co., Ltd. engages in the manufacture and distribution of pharmaceutical products. Its business activities include the production and sale of capsules, small-volume injection, tablet, granules, bran paste agent, freeze-dried powder, oral solution; production and sale of medicine for respiratory disease; and cardiovascular disease prevention and treatment. The company also engages in the export of self-produced products and related technology; import of raw and auxiliary materials; machinery and equipment; spare parts and related technologies as required by company's production and research.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.